HeraMED CEO David Groberman talks about the company’s progress
The Mayo Clinic has been established for more than 150 years, and employs more than 4500 physicians and scientists along with 54,000 allied health staff across 19 hospitals in five US states. It has been ranked No 1 hospital in the world for three years in a row by US news and world reports.
It is also an important partner to Medical technology group HeraMED Limited (ASX:HMD), which has gone from strength to strength since listing on the ASX in December 2018, excelling in the area of product development and distribution, but also forging alliances with other global, high profile medical institutions.
Recently, HeraMED CEO David Groberman sat down with Investor Stream to discuss the Mayo Clinic relationship, recent FDA clearance for HeraBEAT and how it is attempting to build acknowledgement and appreciation amongst medical professionals.
HeraMED has had a strong month of newsflow, firstly with its 510(k) application (K191110) for the company’s HeraBEAT US foetal ultrasonic heart rate monitor (HeraBEAT US) cleared by the US Food and Drug Administration (FDA).
Secondly, with the company announcing that it has entered into an agreement with leading midwife service provider, Kinderheldin GmbH.
Kinderheldin (www.kinderheldin.de) is a leading midwife service provider based in Berlin, which has developed a web based, online platform that offers expecting parents access to large number of midwives through online chat services or telephones.
HeraMED chief executive and co-founder David Groberman said, “This agreement provides HeraMED with a significant differentiator and competitive advantage.
‘’Having a midwifery service that expecting mothers and new parents can access as part of our service offering puts the company leagues ahead as it pushes further into telehealth and connected care.
“Kinderheldin is a tremendous partner for HeraMED as it boasts strong relationships with some of Germany’s oldest and largest insurance companies and hospital groups.
“We look forward to progressing discussions with the top-tier organisations in their network with the aim to implement HeraBEAT and potentially HeraCARE more broadly.”
We expect plenty more news to flow from the company over the coming months and will keep you abreast of all developments.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.